Redeye provides a research update following the Q3 report published by OncoZenge earlier today. Overall, the report did not contain any financial surprises. The company continues its low operating expense and cash burn level, even as it intensifies preparations for the upcoming phase III trial. With a strengthened financial outlook, an initiated collaboration with UCLA and a CTA application in sight, we argue that OncoZenge is on a promising trajectory.
LÄS MER
